Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Gross Margin: 2010-2025

Historic Gross Margin for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to 99.86%.

  • Lineage Cell Therapeutics' Gross Margin rose 87.00% to 99.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 97.84%, marking a year-over-year increase of 284.00%. This contributed to the annual value of 96.48% for FY2024, which is 399.00% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Gross Margin stood at 99.86% for Q3 2025, which was up 1.29% from 98.59% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Gross Margin peaked at 99.86% during Q3 2025, and registered a low of 1.93% during Q4 2021.
  • Moreover, its 3-year median value for Gross Margin was 96.06% (2023), whereas its average is 95.00%.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Gross Margin crashed by 6,596bps in 2021 and then surged by 9,275bps in 2022.
  • Lineage Cell Therapeutics' Gross Margin (Quarterly) stood at 1.93% in 2021, then surged by 9,275bps to 94.67% in 2022, then tumbled by 693bps to 87.74% in 2023, then spiked by 689bps to 94.63% in 2024, then skyrocketed by 87bps to 99.86% in 2025.
  • Its Gross Margin was 99.86% in Q3 2025, compared to 98.59% in Q2 2025 and 97.60% in Q1 2025.